with an increase in c-Myc levels. These perturbations in HEXIM1 and c-Myc expressions increased the in vitro growth of the AML cells. However, HEXIM1 knockdown appeared to exert little effect on the in vivo growth of MOLM13-HKD cells, as the survival of the NOD/SCID mice engrafted with MOLM13-HKD cells was similar to those engrafted with MOLM13-NT cells. As noted above, BRD4 may directly recruit pTEFb to activate transcription, or the ET domain of BRD4 may activate transcription independent of pTEFb by recruiting the arginine demethylase JMJD6 or NSD3.
Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)
Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner
Leukemia (2016) 30, 508-513; doi:10.1038/leu.2015.144
Chromosomal rearrangements of the mixed lineage leukemia (MLL) gene, which result in expression of MLL-fusion proteins, occur in 5-10% of both acute myeloid leukemia and acute lymphoid leukemia. 1 MLL leukemia patients have very unfavorable prognoses, 1,2 emphasizing the need for new therapies. The MLLfusion proteins retain the N-terminal portion of MLL fused with 1 of 470 different fusion partners, classified based on their cellular localization as nuclear and cytoplasmic proteins. 3, 4 It has been proposed that molecular mechanism of transformation used by different MLL fusions is dependent on the type of fusion partner. 4 The MLL fusions harboring nuclear fusion partners (for example, AF4, AF9, ENL, AF10, ELL) are frequently associated with transcriptional elongation complexes leading to transcriptional activation of target genes, while cytoplasmic fusion partners of MLL (for example, AF6, AF1p, GAS7) contain dimerization domains required for transformation. 4, 5 The high diversity of MLL fusion partners raises a question whether it is possible to develop a general therapeutic strategy to block the oncogenic activity of MLL-fusion proteins in a fusion partner-independent manner.
The protein menin was shown to directly interact with the N-terminal fragment of MLL retained in all MLL-fusion proteins, and this interaction is critical for the MLL-fusion protein-mediated transformation. 6, 7 Therefore, blocking the menin-MLL interaction could inhibit oncogenic activity of all MLL-fusion proteins, providing a rationale for a general therapeutic strategy for MLL leukemia patients. To address this important question, we Accepted article preview online 18 June 2015; advance online publication, 21 July 2015 employed MI-2-2, a potent small molecule inhibitor of the menin-MLL interaction (IC 50 = 46 nM), which we have previously shown to be effective in MLL leukemia cells harboring MLL-AF9 and MLL-AF4 fusion proteins. 8 This study was performed to assess whether pharmacologic inhibition of the menin-MLL interaction can block oncogenic activity of a broader panel of MLL-fusion proteins harboring different fusion partners and whether this may represent a general Letters to the Editor therapeutic approach for MLL leukemia. For this purpose, we generated cell lines by transforming murine bone marrow cells with six various MLL fusions representing the major types of MLL translocations: MLL-AF9 and MLL-ENL, the most frequent fusions involving nuclear partners; MLL-CBP, representing fusion with a nuclear protein that acts through a mechanism involving histone acetyltransferase activity; 4 MLL-AF6, one of the most frequent cytoplasmic fusion partner, which dimerizes and may trigger RAS activation; 9 MLL-GAS7 and MLL-AF1p, both harbor cytoplasmic fusion partners that function through dimerization-dependent mechanisms. 5 First, we found that treatment with MI-2-2 resulted in strong growth inhibition of all MLL fusion-transformed cell lines, but not in control cell lines transformed with Hoxa9-Meis1 (HM-2) or E2A-HLF oncogenes (Figure 1a and Supplementary Figure 1) . We then evaluated whether MI-2-2 is capable to induce differentiation of bone marrow cells transformed with different MLL fusions. Indeed, treatment with MI-2-2 led to significant changes in morphology of these cells, consistent with monocytic differentiation (Figure 1b and Supplementary Figure 2) . This was associated with a significant decrease in expression level of c-kit (CD117), a cell surface marker of hematopoietic progenitor cells (Figure 1b Overexpression of HOXA genes represents a hallmark of MLLrearranged leukemias, 10 and menin is required for Hoxa9 and Meis1 expression. 6 Indeed, treatment with MI-2-2 resulted in a marked downregulation of Hoxa9 and Meis1 expression in cells expressing different MLL fusions (Figure 1b To better understand the mechanism how MI-2-2 blocks oncogenic activity of different MLL fusions, we selected one cell line transformed with nuclear fusion partner (MLL-AF9) and two with cytoplasmic fusion partners (MLL-AF6 and MLL-AF1p). It was proposed that Hoxa9 activation by MLL fusions encompassing nuclear fusion partners involves assembly of multi-protein complexes, which results in epigenetic reprograming by increasing the H3K79 and H3K4 methylation. 4 On the other hand, the mechanism of Hoxa9 activation by MLL fusions involving cytoplasmic fusion partners is much less understood. 4 To characterize how MI-2-2 downregulates Hoxa9 expression, we performed co-immunoprecipitation experiments. First, we found that treatment with MI-2-2 strongly reduced binding of both menin and MLL fusions to the Hoxa9 loci in all three MLL leukemia cell lines (Figure 1d and Supplementary Figure 5 ). In addition, MI-2-2 significantly reduced methylation level of H3K79 and H3K4 at Hoxa9 promoter, consistent with decreased transcriptional activation of Hoxa9 (Figure 1d and Supplementary Figure 5 ). These data suggest that MI-2-2 downregulates Hoxa9 according to a similar mechanism despite different complexes formed by these MLL fusions. 4 To explore genome-wide transcriptome analysis on inhibition of the menin-MLL interaction, we performed RNA-seq analysis in MLL-AF9-, MLL-AF6-and MLL-AF1p-transformed cells. First, we found that treatment with MI-2-2 results in a very similar pattern of gene expression changes in these cell lines (Figure 2a ). The expression level of the downstream targets of MLL-fusion proteins, such as Hoxa9, Meis1, Hoxa10, Hoxa5 and Hoxa11, was significantly reduced in all cell lines after treatment with MI-2-2 (Supplementary Table 1 ). In addition, other genes implicated in MLL leukemias, CDK6, Eya1, Six1 and Six4, 11 were also strongly downregulated. Gene set enrichment analysis demonstrated strong enrichment for direct target genes of MLL-AF9 (ref. 12) in all cell lines (Figure 2c ). Overall, these results demonstrate that MI-2-2 is reversing gene expression signature in MLL-rearranged cells in a fusion partner-independent manner.
One of the most pronounced phenotypic changes observed on treatment with MI-2-2 is a marked differentiation of MLL leukemia cells (Figure 1b) . Consistent with this finding, MI-2-2 upregulates genes associated with differentiation (for example, CD14, MNDA), Supplementary Table1, and Gene Set Enrichment Analysis demonstrates strong enrichment for genes repressed in leukemia-stem cells (CD34 + CD38 − cells), Figure 2d . 13 These effects were observed in all MLL leukemia cell lines tested, supporting a similar mechanism of action for the menin-MLL inhibitor despite different MLL-fusion proteins expressed.
Interestingly, only a subset of genes affected by MI-2-2 (20-30% of upregulated genes and 38-50% of downregulated genes) is ) and IgG (Milipore, PP64B) were used. Real-time PCR was performed on the precipitated DNAs with TaqMan fluorescent labeling with primers and quantitative PCR probes (Hoxa9 primer probe set 1, P1; and Hoxa9 primer probe set 2, P2; primers sequences as described previously 15 ). The P-values were calculated with two-way analysis of variance, *P o0.05, **Po 0.01. No statistical method was used to predetermine sample size.
identical among the three cell lines tested (Figure 2b ), despite the fact these cell lines were created from the same cellular background. These results suggest that transformation with different MLL fusions, such as MLL-AF9, MLL-AF6 or MLL-AF1p, leads to substantial differences between these cells. Nevertheless, all these cell lines overexpress subset of genes that are downstream targets of MLL fusions and are sensitive to inhibition of the menin-MLL interaction by small molecules. 
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To further support general applicability of the menin-MLL inhibitors, we tested the effect of MI-2-2 in primary samples isolated from MLL leukemia patients harboring different MLL translocations, including nuclear and cytoplasmic fusion partners. In the clonogenic assay, treatment with MI-2-2 substantially reduced the number and size of colonies in all samples harboring various MLL fusions, but not in the control acute myeloid leukemia samples (Figures 2e and f, Supplementary Figure 6 and Supplementary Table 2 ). Finally, we assessed the in vivo efficacy of the menin-MLL inhibitor MI-463, an optimized analog of MI-2-2 with substantially improved pharmacokinetic profile, 14 using a bone marrow transplantation model of murine MLL-AF6 leukemia. Treatment with MI-463 greatly improved survival (~35% survival benefit) of MLL-AF6 mice (Figure 2g) , consistent with the effect we observed for this compound in MLL-AF9 leukemia mice. 14 In conclusion, our studies demonstrate that small molecule inhibition of the menin-MLL interaction leads to growth arrest, differentiation and downregulation of MLL-fusion target genes in leukemia cells transformed with various MLL fusions, and affects colony formation in leukemia patient samples harboring different MLL translocations. Furthermore, menin-MLL inhibitor blocks binding of both menin and MLL and/or MLL fusions to Hoxa9 loci, consistent with co-localization of these proteins to the target genes, 6 and decreases H3K4 and H3K79 methylation in cell lines transformed with MLL-AF9, MLL-AF6 and MLL-AF1p, despite different protein complexes formed by these MLL fusions. 4 Genome-wide analysis of gene expression revealed that MI-2-2 reverses MLL-rearranged gene signature and induced expression of genes associated with differentiation in cells harboring various MLL-fusion proteins. Taken together, the menin-MLL inhibitor is capable of reversing oncogenic activity of different MLL fusions according to a mechanism that is independent of the fusion partner. Such activity remains to be in agreement with meninbinding motif retained in all MLL-fusion proteins. This is further validated by the studies with our new menin-MLL inhibitor with improved pharmacokinetics, 14 which demonstrate that blocking the menin-MLL interaction markedly improves survival in animal model of MLL-AF6 leukemia. Altogether, these studies demonstrate that pharmacologic inhibition of the menin-MLL interaction has a strong potential to represent a general therapeutic approach for MLL leukemias regardless of MLL translocation, a highly desired effect due to a large variability of MLL fusion partners. These findings further support advancement of menin-MLL inhibitors as a targeted therapy for the MLL leukemia patients.
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The phosphoproteomic profile was determined by Reverse Phase Protein micro-Array (RPPA), a quantitative multiplex immunoassay allowing concomitant measurement of the expression of a given (phospho)protein across hundreds of samples using a single antibody. 6 A complete list of stained antibodies, along with details of the RPPA procedure, and of all the procedures applied in the present study are reported in Supplementary Table S2 Table S1 ).
Comparison of the proteomic profiles between CD49d + and CD49d − CLL cells highlighted the overexpression in CD49d + CLL of phosphoproteins involved in the integrin-mediated actin regulation signaling, 7 including phospho-p21-activated kinase (PAK1 S199-204/PAK2 S192-197; phospho-PAK1/2; pPAK; P = 0.0005), phospho-Lin-11/Isl-1/Mec-3 kinase (LIMK1 T508/LIMK2 T505; phospho-LIMK1/2; pLIMK; P = 0.00001; Figure 1a) , and phosphov-crk homolog (CrkII Y221, P = 0.039; Supplementary Table S3 ). The constitutive pPAK and pLIMK overexpression in the circulating CD49d + CLL cells was confirmed by western blot analysis of additional freshly isolated CLL cells (P = 0.04 and P = 0.01 for pPAK and pLIMK respectively, Figure 1b) . pPAK expression was strongly correlated with expression of the downstream protein pLIMK across CD49d + CLL cases (r = 0.7, P = 0.005). Moreover, a correlation analysis performed with all the proteins belonging to the actin regulation pathway (16 proteins, Supplementary Table S2 and Supplementary Figure S1 ) evidenced a higher protein correlation in CD49d + (r ⩾ 0.6 in 24/120 pair comparisons) compared with CD49d − CLL cells (r ⩾ 0.6 in 3/120 pair comparisons), suggesting that the phosphoproteomic profile of circulating CD49d + CLL cells was overall consistent with the integrin pathway activation. 8 The phosphorylated status of both PAK and LIMK was transient, as demonstrated by the loss of pPAK and pLIMK expression by CD49d + CLL cells cultured ex vivo in serum-free conditions (1 h at 37°C; data not shown). Given this phenomenon, it is likely that PAK and LIMK phosphorylation due to CD49d engagement, as it occurs in lymphoid tissues, is no longer detectable when CLL cells are released from the tissue compartments. Therefore, the activated integrin pathway observed in circulating CD49d + CLL cells was more likely to be ascribed to a continuous CD49d
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